http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2004321682-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5ef4e459dae0beb9149db1eec84d20ee |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J20-24 |
| filingDate | 2003-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b830a3af08c223d9fc691e64770e9f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4140e096cf3b58b0f9bebee6f3c5255 |
| publicationDate | 2004-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2004321682-A |
| titleOfInvention | Adsorbent for blood purification and method for treating IgA nephropathy using the same |
| abstract | The object of the present invention is to provide an adsorbent for blood purification that adsorbs and removes abnormal sugar chain-type IgA1, "abnormal sugar chain-type IgA1 cellular fibronectin complex" and further IgA2 in the blood of patients with IgA nephropathy. And a method for treating the same. The adsorbent for blood purification of the present invention is characterized by comprising "jacalin and / or a jacalin derivative" which specifically binds to IgA2, or an abnormal sugar chain type IgA1 and an "abnormal sugar chain type IgA1 cellular fibronectin complex". It is a "heat-treated jacalin hydrolyzate" that specifically binds, and is composed of a structure in which the adsorbent is immobilized on a water-insoluble carrier, and is suitably used for the treatment of IgA nephropathy. [Selection diagram] Fig. 1 |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009001512-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017527553-A |
| priorityDate | 2003-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.